Crescent BiopharmaCBIO
13F holders, Q1 2026 (March 31)3holders +1
1new positions
0sold out
$18.37avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Crescent Biopharma Inc. (CBIO) in their 13F filings, up 1 from Q4 2025. 1 opened new positions and 0 sold out. The largest holders were Boxer Capital Management, LLC ($8.3M), Remedium Capital Partners, LLC ($6.6M) and Quadrature Capital Ltd ($384K).
- Company
- Crescent Biopharma Inc.
- CUSIP
- 38000Q201
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $8.3M |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 461,357 shares bought, net +461,357 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Boxer Capital Management, LLC | 1.09% | New | 453,686 | $8.3M |
| Remedium Capital Partners, LLC | 2.36% | No change | 361,250 | $6.6M |
| Quadrature Capital Ltd | 0.00% | Add +57.9% | 20,917 | $384K |
"% of holder's portfolio" is CBIO's weight in each manager's 13F, not the share of Crescent Biopharma Inc. the manager owns.